Conveglipron (INN; developmental code name HDM1002) is a glucagon-like peptide-1 (GLP-1) receptor agonist which is under development for the treatment of type 2 diabetes, obesity, and diabetes mellitus.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.